Leu-AMS |
| Catalog No.GC32121 |
Leu-AMS (composé 6), un analogue de la leucine, est un puissant inhibiteur de la leucyl-ARNt synthétase (LRS) avec une IC50 de 22,34 nM, qui inhibe l'activité catalytique du LRS mais n'affecte pas l'activation de mTORC1 induite par la leucine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 288591-93-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Leu-AMS is a potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM and inhibits the growth of bacteria.
Leu-AMS is proved to be a potent inhibitor of Leucyl-tRNA Synthetase (LRS) with an IC50 value of 22.34 nM. Leu-AMS is highly cytotoxic in both cancer cells and normal cells. Leu-AMS does not affect S6 kinase (S6K) phosphorylation at all. Leu-AMS inhibits the catalytic activity of LRS but does not affect the leucine-induced mTORC1 activation[1].
[1]. Yoon S, et al. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-TargetedMammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. J Med Chem. 2016 Nov 23;59(22):10322-10328.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *